Das könnte Sie auch interessieren:

Silberne Bären und GWFF Preis für ZDF-Produktionen bei der 69. Berlinale / "Systemsprenger", "Ich war zuhause, aber" und "Oray" ausgezeichnet

Mainz (ots) - Bei den 69. Internationalen Filmfestspielen in Berlin wurde "Systemsprenger", eine Koproduktion ...

"Scheunenfund": Erster Bulli-Radarblitzer nach 54 Jahren entdeckt

Hannover (ots) - - T1 war zu Schulungszwecken bei der Polizei Niedersachsen im Einsatz - 66 Jahre ...

20.09.2017 – 19:01

deCODE genetics

deCODE Study Reveals an Ancient Achilles Heel in the Human Genome

Reykjavik, Iceland (ots/PRNewswire)

- The generation of new mutations is a  key driver of evolution  but 
  also of  susceptibility to  rare  diseases
- Fathers pass  on  four times as many new mutations as  mothers do, 
  but  the  maternal contribution is particularly  strong  in  10%  
  of the genome  that is prone to double-strand breaks in the helix 
  structure of DNA
- These regions have been mutational hotspots for a very long time, 
  and they are found in  chimpanzees and gorillas but not orangutans
- This study provides  the  most comprehensive catalogue of de novo 
  mutations to date  - an important reference  set for improving the 
  diagnosis of rare diseases 

In a major study published today, researchers at deCODE genetics use whole-genome data from 14,000 people from across the population of Iceland, including 1500 sets of parents and children, to provide the most detailed portrait to date of how sequence diversity in humans is the result of an evolving interaction between sex, age, mutation type and location in the genome. "Parental influence on human germline de novo mutations in 1,548 trios from Iceland" is published today in the online edition of Nature.

(Logo: http://mma.prnewswire.com/media/558806/deCODE_genetics_Logo.jpg )

"This is an important new chapter in our ongoing work to understand the mechanisms driving genomic diversity and through that the evolution of our species," said Kari Stefansson, CEO of deCODE and senior author on the paper. "De novo or new mutations provide an important part of the substrate for evolution, launching a constant flow of new versions of the human genome into the environment. However, they are also believed to be responsible for the majority of cases of rare diseases of childhood. Providing a comprehensive catalogue of such mutations from across an entire population is therefore not just scientifically interesting but also an important contribution to improving rare disease diagnostics."

Today's study shows that in about 10% of the genome, the de novo mutations coming from the mother equal in number the ones coming from the father. Most of the maternally derived de novo mutations in these regions are C-to-G (C>G) mutations and are rooted in flaws in the repair of double-strand breaks. The density of C>G SNPs in this 10% of the genome is also very high, with considerable variability in the frequency of the less common allele. This indicates that these regions of the genome have been vulnerable to double-strand breaks for a very long time. These same regions of the genome also show a high density of C>G SNPs in chimpanzees, less so in gorillas, and not at all in orangutans.

"The frequency of de novo mutations in this 10% of the genome is almost twice that in the rest of the genome. By definition the attributes conferred on us by genes in this region must evolve faster than other attributes," Dr Stefansson added.

This study leverages deCODE's unique genetics resources in Iceland to build upon earlier results linking parental age and sex to variability in recombination and various types of mutation. De novo mutations are so called because they are generated during the formation of eggs and sperm, they can be passed to offspring but are not seen in the parents. The deCODE team was able to develop such a large dataset and catalogue of these mutations correlating whole-genome sequence data from thousands of individuals and multiple generations of families with information on the age of parents at the time their children were born.

Based in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease. deCODE is a wholly-owned subsidiary of Amgen (NASDAQ:AMGN).


Jon Gustafsson

deCODE genetics


Edward Farmer

for deCODE genetics



Original-Content von: deCODE genetics, übermittelt durch news aktuell

Alle Meldungen
Abonnieren Sie alle Meldungen von deCODE genetics
  • Druckversion
  • PDF-Version

Orte in dieser Meldung

Themen in dieser Meldung